AQR Capital Management LLC Sells 1,188,452 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO)

AQR Capital Management LLC cut its stake in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) by 43.8% during the 4th quarter, Holdings Channel reports. The fund owned 1,522,154 shares of the company’s stock after selling 1,188,452 shares during the period. AQR Capital Management LLC’s holdings in Organogenesis were worth $4,871,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Virtu Financial LLC purchased a new position in shares of Organogenesis in the 4th quarter worth approximately $38,000. Palumbo Wealth Management LLC bought a new stake in Organogenesis during the 4th quarter worth approximately $65,000. Aquatic Capital Management LLC purchased a new position in Organogenesis during the fourth quarter worth about $111,000. MetLife Investment Management LLC grew its stake in Organogenesis by 34.9% in the 4th quarter. MetLife Investment Management LLC now owns 36,593 shares of the company’s stock worth $117,000 after buying an additional 9,465 shares in the last quarter. Finally, Mariner LLC bought a new position in Organogenesis in the fourth quarter valued at $123,000. Institutional investors own 49.57% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley upped their price objective on shares of Organogenesis from $4.00 to $6.00 and gave the company an “equal weight” rating in a research note on Wednesday, March 5th.

Insider Buying and Selling at Organogenesis

In other Organogenesis news, Director Michael Joseph Driscoll sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $5.10, for a total value of $127,500.00. Following the completion of the transaction, the director now directly owns 166,879 shares in the company, valued at $851,082.90. This represents a 13.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 36.90% of the company’s stock.

Organogenesis Price Performance

ORGO stock opened at $5.34 on Friday. Organogenesis Holdings Inc. has a 1 year low of $2.21 and a 1 year high of $6.71. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74. The firm has a 50-day moving average of $4.69 and a 200 day moving average of $3.90. The company has a market cap of $677.40 million, a P/E ratio of -89.00 and a beta of 1.85.

Organogenesis (NASDAQ:ORGO) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.10). Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. On average, sell-side analysts forecast that Organogenesis Holdings Inc. will post -0.07 EPS for the current year.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.